GeoVax Labs (NASDAQ:GOVX) Downgraded to “Hold” Rating by D. Boral Capital

GeoVax Labs (NASDAQ:GOVX) was downgraded by stock analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Other equities analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Wall Street Zen cut shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, GeoVax Labs has a consensus rating of “Hold” and an average price target of $187.50.

GeoVax Labs Stock Down 12.0%

GeoVax Labs stock opened at $1.39 on Thursday. The business’s 50-day moving average price is $3.89 and its 200 day moving average price is $11.00. The firm has a market cap of $2.40 million, a price-to-earnings ratio of -0.04 and a beta of 3.77. GeoVax Labs has a 52 week low of $1.26 and a 52 week high of $47.13.

Institutional Trading of GeoVax Labs

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the fourth quarter valued at about $99,000. HRT Financial LP acquired a new stake in GeoVax Labs during the 4th quarter worth approximately $31,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Hudson Bay Capital Management LP purchased a new stake in shares of GeoVax Labs during the third quarter worth approximately $47,000. Finally, Armistice Capital LLC purchased a new position in GeoVax Labs in the 3rd quarter valued at $253,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.